Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 635-641

  Herscher, Laurie L ^a   Hahn, Stephen M ^a   Kroog, Glenn ^a   Pass, Harvey ^a   Temeck, Barbara ^a   Goldspiel, Barry ^a   Cook, John ^a   Mitchell, James B ^a   Liebmann, James ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MESOTHELIOMA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIVITY;

EID: 0031917868     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.635     Document Type: Article

References (38)

1. Perez CA, Pajak TF, Rubin P, et al: Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Cancer 59:1874-1881, 1987
2. Johnson DH, Einhorn LH, Bartolucci A, et al: Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 113:33-38, 1990
3. Antman KH: Malignant mesothelioma. N Engl J Med 303:200-202, 1980
4. Mountain CF: A new international staging system for lung cancer. Chest 89:225S-233S, 1986
5. Dillman RO, Seagren SL, Propert KJ, et al: A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940-945, 1990
6. Schaake-Koning C, van den Bogaert W, Dalesto O, et al: Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:524-530, 1992
7. Arriagada R, Le Chevalier T, Quoix E, et al: ASTRO plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients. Int J Radiat Biol Phys 20:1183-1190, 1991
8. Sause WT, Scott C, Taylor S, et al: Radiation Therapy Oncology Group 88-08 and Eastern Cooperative Oncology Group 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205, 1995
9. Carmichael J, DeGraff WG, Gamson J, et al: Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol 25:527-534, 1989
10. Mattson K, Holsti LR, Tammilehto L, et al: Multimodality treatment programs for malignant pleural mesothelioma using high-dose hemithorax irradiation. Int J Radiat Biol Phys 24:643-650, 1992
11. Thigpen JT, Blessing JA, Ball H, et al: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A gynecologic Oncology Group Study. J Clin Oncol 12:1748-1753, 1994
12. Einzig AI, Wiernik PH, Sasloff J, et al: Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748-1753, 1992
13. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
14. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
15. Murphy WK, Fossella FV, Winn RJ, et al: Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
16. Chang AY, Kim K, Click J, et al: Phase II study of taxol, merbarone and piraxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 85:388-394, 1993
17. Johnson DH, Chang AY, Ettinger DS: Taxol (paclitaxel) in the treatment of lung cancer: The Eastern Cooperative Oncology Group experience. Ann Oncol 5:S45-S50, 1994
18. Manfredi JJ, Parness J, Horwitz SB: Taxol binds to cellular microtubules. J Cell Biol 94:688-696, 1982
19. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277:665-667, 1979
20. Terasima T, Tolmach LJ: Changes in x-ray sensitivity of HeLa cells during the division cycle. Nature 190:1210-1211, 1961
21. Liebmann J, Cook JA, Fisher J, et al: Changes in radiation survival curve parameters in human tumors and rodent cells exposed to paclitaxel. Int J Radiat Oncol Biol Phys 29:559-564, 1994
22. Liebmann J, Cook JA, Fisher J, et al: In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 86:441-446, 1994
23. Tishler RB, Geard CR, Hall EJ, et al: Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52:3495-3497, 1992
24. Tishler RB, Schiff PB, Geard CR: Taxol: A novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613-617, 1992
25. Spriggs DR, Tondini C: Taxol administered as a 120-hour continuous infusion. Invest New Drugs 10:275-278, 1992
26. Herskovic A, Martz K, Al-Sarraf M, et al: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593-1598, 1992
27. O'Connell MJ, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994
28. Steren A, Sevin B-U, Perras J: Taxol sensitizes human ovarian cancer cells to radiation. Gynecol Oncol 48:252-258, 1993
29. Choy H, Rodriguez FF, Koester S: Investigation of taxol as a potential radiation sensitizer. Cancer 71:3774-3778, 1993
30. Wilson WH, Berg S, Kang Y-K: Phase I/II study of taxol 96-hour infusion in refractory lyphoma and breast cancer: Pharmacodynamics and analysis of multi-drug resistance (mdr1). Proc Amer Soc Clin Oncol 12:134, 1993 (abstr 335)
31. Liebmann J, Cook JA, Lipschultz C, et al: The influence of Cremophor EL on the cell cycle effects of paclitaxel in human tumor cell lines. Cancer Chem Pharmacol 33:331-339, 1994
32. Hahn SM, Liebmann JL, Cook J, et al: Taxol in combination with doxrubicin or etoposide. Cancer 72:2705-2711, 1993
33. Mason KA, Milas M, Peters LJ: Effect of paclitaxel (taxol) alone and in combination with radiation on the gastrointestinal mucosa. Int J Radiat Biol Phys 32:1381-1389, 1995
34. Milas L, Hunter NR, Mason KA, et al: Enhancement of tumor radioresponse of a murine mammary carcinoma by taxol. Cancer Res 54:3506-3510, 1994
35. Milas L, Hunter NR, Kurdoglu B, et al: Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol (paclitaxel). Cancer Chemother Pharmacol 35:297-303, 1995
36. Choy H, Akerley W, Safran H, et al: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12:2682-2686, 1994
37. Rosenthal DI, Close LG, Lucci JA, et al: Phase I studies of continuous-infusion paclitaxel given with standard aggressive radiation therapy for locally advanced solid tumors. Semin Oncol 22:13-17, 1995
38. Skubitz KM: A phase I study of ambulatory continuous infusion paclitaxel. Proc Am Soc Clin Oncol 14:486, 1995 (abstr 1584)